PortalPublikationenCardiac Tissue Engineering State of the Art

Cardiac Tissue Engineering State of the Art

Standard

Cardiac Tissue Engineering State of the Art. / Hirt, Marc N; Hansen, Arne; Eschenhagen, Thomas.

in: CIRC RES, Jahrgang 114, Nr. 2, 17.01.2014, S. 354-367.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hirt, MN, Hansen, A & Eschenhagen, T 2014, 'Cardiac Tissue Engineering State of the Art', CIRC RES, Jg. 114, Nr. 2, S. 354-367. https://doi.org/10.1161/CIRCRESAHA.114.300522

APA

Hirt, M. N., Hansen, A., & Eschenhagen, T. (2014). Cardiac Tissue Engineering State of the Art. CIRC RES, 114(2), 354-367. https://doi.org/10.1161/CIRCRESAHA.114.300522

Vancouver

Hirt MN, Hansen A, Eschenhagen T. Cardiac Tissue Engineering State of the Art. CIRC RES. 2014 Jan 17;114(2):354-367. https://doi.org/10.1161/CIRCRESAHA.114.300522

Bibtex

@article{76b32b97fc6a4e1c9cb60cec084a530e,
title = "Cardiac Tissue Engineering State of the Art",
abstract = "The engineering of 3-dimensional (3D) heart muscles has undergone exciting progress for the past decade. Profound advances in human stem cell biology and technology, tissue engineering and material sciences, as well as prevascularization and in vitro assay technologies make the first clinical application of engineered cardiac tissues a realistic option and predict that cardiac tissue engineering techniques will find widespread use in the preclinical research and drug development in the near future. Tasks that need to be solved for this purpose include standardization of human myocyte production protocols, establishment of simple methods for the in vitro vascularization of 3D constructs and better maturation of myocytes, and, finally, thorough definition of the predictive value of these methods for preclinical safety pharmacology. The present article gives an overview of the present state of the art, bottlenecks, and perspectives of cardiac tissue engineering for cardiac repair and in vitro testing.",
keywords = "Animals, Heart Diseases, Humans, Myocardium, Myocytes, Cardiac, Recovery of Function, Regeneration, Regenerative Medicine, Tissue Engineering",
author = "Hirt, {Marc N} and Arne Hansen and Thomas Eschenhagen",
year = "2014",
month = jan,
day = "17",
doi = "10.1161/CIRCRESAHA.114.300522",
language = "English",
volume = "114",
pages = "354--367",
journal = "CIRC RES",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

RIS

TY - JOUR

T1 - Cardiac Tissue Engineering State of the Art

AU - Hirt, Marc N

AU - Hansen, Arne

AU - Eschenhagen, Thomas

PY - 2014/1/17

Y1 - 2014/1/17

N2 - The engineering of 3-dimensional (3D) heart muscles has undergone exciting progress for the past decade. Profound advances in human stem cell biology and technology, tissue engineering and material sciences, as well as prevascularization and in vitro assay technologies make the first clinical application of engineered cardiac tissues a realistic option and predict that cardiac tissue engineering techniques will find widespread use in the preclinical research and drug development in the near future. Tasks that need to be solved for this purpose include standardization of human myocyte production protocols, establishment of simple methods for the in vitro vascularization of 3D constructs and better maturation of myocytes, and, finally, thorough definition of the predictive value of these methods for preclinical safety pharmacology. The present article gives an overview of the present state of the art, bottlenecks, and perspectives of cardiac tissue engineering for cardiac repair and in vitro testing.

AB - The engineering of 3-dimensional (3D) heart muscles has undergone exciting progress for the past decade. Profound advances in human stem cell biology and technology, tissue engineering and material sciences, as well as prevascularization and in vitro assay technologies make the first clinical application of engineered cardiac tissues a realistic option and predict that cardiac tissue engineering techniques will find widespread use in the preclinical research and drug development in the near future. Tasks that need to be solved for this purpose include standardization of human myocyte production protocols, establishment of simple methods for the in vitro vascularization of 3D constructs and better maturation of myocytes, and, finally, thorough definition of the predictive value of these methods for preclinical safety pharmacology. The present article gives an overview of the present state of the art, bottlenecks, and perspectives of cardiac tissue engineering for cardiac repair and in vitro testing.

KW - Animals

KW - Heart Diseases

KW - Humans

KW - Myocardium

KW - Myocytes, Cardiac

KW - Recovery of Function

KW - Regeneration

KW - Regenerative Medicine

KW - Tissue Engineering

U2 - 10.1161/CIRCRESAHA.114.300522

DO - 10.1161/CIRCRESAHA.114.300522

M3 - SCORING: Journal article

C2 - 24436431

VL - 114

SP - 354

EP - 367

JO - CIRC RES

JF - CIRC RES

SN - 0009-7330

IS - 2

ER -